Core Viewpoint - Lai Kai Pharmaceutical-B (02105.HK) announced positive preliminary results from the Phase I Multiple Ascending Dose (MAD) study of LAE102 for the treatment of obesity in China [1] Group 1: Study Overview - The MAD study is a randomized, double-blind, placebo-controlled trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE102 in overweight/obese subjects [1] - The study enrolled participants with an average Body Mass Index (BMI) of 29.4 kg/m², including three ascending dose groups (2 mg/kg, 4 mg/kg, and 6 mg/kg), with weekly subcutaneous administration for four weeks [1] Group 2: Preliminary Results - Initial results show a promising trend in muscle gain and fat loss, with the 6 mg/kg dose group experiencing an average lean body mass increase of 1.7% compared to baseline, while average fat mass decreased by 2.2% [1] - After adjusting for the placebo group, the average lean body mass increase reached 4.6%, and the average fat mass reduction was 3.6% [1]
来凯医药-B(02105.HK)：I期临床MAD研究取得积极初步结果LAE102展现出令人鼓舞的增肌减脂趋势